Vaxcyte (PCVX) Operating Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Operating Expenses data on file, last reported at $345.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 91.3% year-over-year to $345.8 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 71.22% increase from a year earlier, with the FY2025 full-year figure at $923.7 million, up 62.18% from the prior year.
• Operating Expenses for Q1 2026 stood at $345.8 million, up from $274.3 million in the prior quarter.
• Over the last five years, Operating Expenses for PCVX reached as high as $345.8 million in Q1 2026 and fell as low as $39.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $149.4 million across 5 years, with a median of $139.9 million in 2024.
• Across the five-year window, Operating Expenses surged 190.07% in 2022 and fell 17.55% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $86.6 million in 2022, then jumped by 127.18% to $196.7 million in 2023, then decreased by 17.55% to $162.2 million in 2024, then surged by 69.13% to $274.3 million in 2025, then rose by 26.09% to $345.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $345.8 million in Q1 2026, $274.3 million in Q4 2025, and $242.4 million in Q3 2025.